Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

ClinicalTrials.gov ID: NCT04128579

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04128579. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis

Study identification

NCT ID
NCT04128579
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Biocon Limited
Industry
Enrollment
52 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2019 (Actual)
Primary completion
Nov 16, 2023 (Actual)
Completion
Jan 18, 2024 (Actual)
Last update posted
Jun 4, 2026

2019 – 2024

United States locations

U.S. sites
19
U.S. states
7
U.S. cities
17
Facility City State ZIP Site status
AKDHC Medical Research Services, LLC Sun City Arizona 85351 —
California Institute of Renal Research Chula Vista California 91910 —
University of California San Diego Perlman Ambulatory Clinic La Jolla California 92037 —
Clinical Research of West Florida - Clearwater Clearwater Florida 33765-2616 —
Centre for Rheumatology, Immunology and Arthritis Fort Lauderdale Florida 33309 —
University of Florida, Division of Rheumatology Gainesville Florida 32610 —
Clinical Site Partners Leesburg, LLC Leesburg Florida 34748 —
SouthCoast Research Center Inc Miami Florida 33136 —
Hope Clinical Trials Miami Florida 33165 —
Omega Research Maitland, LLC Orlando Florida 32810 —
Clinical Research of West Florida - Tampa Tampa Florida 33603 —
University of South Florida Tampa Florida 33606 —
Georgia Nephrology Lawrenceville Georgia 30046 —
Northwell Health / Division of Rheumatology Great Neck New York 11021 —
Columbia University Medical Center, Div of Nephrology New York New York 10032 —
Albert Einstein College of Medicine, Montefiore Medical Center The Bronx New York 10461 —
Northeast Clinical Research Center, LLC Bethlehem Pennsylvania 18017 —
Dallas Renal Group Dallas Texas 75230 —
Prolato Clinical Research Center (PCRC) Houston Texas 77054 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04128579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 4, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.